FTC/TDF

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Chronic HepatitisImmunodeficiencyHIV-1 InfectionHuman Immunodeficiency Virus (HIV)

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

1

FTC/TDF

Gilead

Phase 3

32

PEG-Intron

Merck & Co.

Preclinical

433

Sovaldi

Gilead

Preclinical

344

Incivek

Vertex Pharmaceuticals

Preclinical

105

Intron a

Sanofi

Preclinical

76

Medrol

Pfizer

Preclinical

17

Dasabuvir

AbbVie

Preclinical

78

SOF/VEL

Gilead

Preclinical

49

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

110

Interferon Alfa

Pfizer

Preclinical

2Show 17 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Tenofovir Disoproxil Fumarate10 trials

Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects

Completed·Gilead·Phase 3·NCT00112047·517 enrolled

Tenofovir Disoproxil Fumarate (Tenofovir DF) Versus Emtricitabine/Tenofovir DF in Subjects Resistant to Lamivudine

Completed·Gilead·Phase 3·NCT00737568·280 enrolled

Evaluating the Safety of and Adherence to a Vaginal Matrix Ring Containing Dapivirine and Oral Emtricitabine/Tenofovir Disoproxil Fumarate in an Adolescent and Young Adult Female Population

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT03593655·247 enrolled

Show 7 more trials

Rollover Protocol Continued Access to Emtricitabine/Tenofovir Disoproxil Fumarate for Adults in United States

Completed·Gilead·Phase 2·NCT00936715·24 enrolled

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 3·NCT01108510·698 enrolled

Safety and Acceptability Study of Oral Emtricitabine/Tenofovir Disoproxil Fumarate Tablet and Rectally-Applied Tenofovir Reduced-Glycerin 1% Gel

Completed·CCONRAD·Phase 2·NCT01687218·195 enrolled

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

Completed·Johnson & Johnson·Phase 3·NCT02269917·1,149 enrolled

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

Completed·Gilead·Phase 3·NCT02616783·167 enrolled

A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy Participants

Completed·Merck & Co.·Phase 1·NCT06816043·20 enrolled

Safety and Efficacy of Cobicistat-boosted Atazanavir Compared to Ritonavir-boosted Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 2·NCT00892437·85 enrolled

Chronic Hepatitis3 trials

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Positive Chronic Hepatitis B

Completed·Gilead·Phase 3·NCT00116805·266 enrolled

Truvada Versus Truvada Plus Hepatitis B Immunoglobulin (HBIg) in Prevention of Chronic Hepatitis B Recurrence Post Liver Transplant

Completed·Gilead·Phase 2·NCT00507689·40 enrolled

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B

Completed·Gilead·Phase 3·NCT00117676·382 enrolled

HIV-1 infection2 trials

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

Terminated·Merck & Co.·Phase 3·NCT04652700·494 enrolled

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)

Terminated·Merck & Co.·Phase 3·NCT04644029·730 enrolled

Safety and Efficacy2 trials

Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults

Completed·Gilead·Phase 3·NCT02603107·578 enrolled

Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

Completed·Gilead·Phase 3·NCT02652624·472 enrolled

Tenofovir2 trials

Study to Evaluate Switching From Regimens Consisting of a Nonnucleoside Reverse Transcriptase Inhibitor Plus Emtricitabine and Tenofovir DF to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed·Gilead·Phase 3·NCT01495702·439 enrolled

Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients

Completed·Gilead·Phase 3·NCT01475838·438 enrolled

10 more indications

Antiretroviral Treatment2 trials

D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults

Completed·Gilead·Phase 2·NCT01565850·153 enrolled

Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

Completed·Gilead·Phase 3·NCT01705574·583 enrolled

Pre-Exposure Prophylaxis (PrEP)2 trials

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-risk Populations in Uganda, Africa

Completed·IInternational AIDS Vaccine Initiative·Phase 1/2·NCT00931346·72 enrolled

A Pilot Study of Pre-Exposure Prophylaxis (PrEP) to Evaluate Safety, Acceptability, and Adherence in At-Risk Populations in Kenya, Africa

Completed·IInternational AIDS Vaccine Initiative·Phase 1/2·NCT00971230·72 enrolled

Human Immunodeficiency Virus (HIV)2 trials

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis in Women

Recruiting·Merck & Co.·Phase 3·NCT07071623·4,580 enrolled

A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of MK-8527 Oral Once-Monthly as HIV-1 Preexposure Prophylaxis

Recruiting·Merck & Co.·Phase 3·NCT07044297·4,390 enrolled

Immunodeficiency1 trial

Study to Evaluate the Safety and Efficacy of Stribild Versus Ritonavir-Boosted Atazanavir Plus Truvada in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

Completed·Gilead·Phase 3·NCT01106586·708 enrolled

Efficacy and Safety1 trial

Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed·Gilead·Phase 1/2·NCT01565889·52 enrolled

HIV-11 trial

Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF

Completed·Gilead·Phase 3·NCT02121795·668 enrolled

Women1 trial

The Kampala Women's Bone Study

Completed·UUniversity of Washington·Phase 4·NCT03464266·500 enrolled

Itching1 trial

Study to Evaluate Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants

Completed·Gilead·Phase 3·NCT01815736·1,443 enrolled

Pregnant Women1 trial

Optimizing PrEP Regimens for Pregnant Women in Sub-Saharan Africa (O-PrEP Study) - Stage 1

Completed·UUniversity of North Carolina, Chapel Hill·Phase 2·NCT06435026·54 enrolled

Bone1 trial

Renal, Endocrine, and Bone Changes in Response to FTC/TDF in Uninfected Young Men Who Have Sex With Men (YMSM).

Completed·UUniversity of North Carolina, Chapel Hill··NCT01769469·101 enrolled

Details

Drug Info

Related News